Curated News
By: NewsRamp Editorial Staff
September 08, 2026
AcroMeta Partners to Revolutionize Cell Logistics with ATCLS Technology
TLDR
- AcroMeta's strategic stake in Macro-ATCLS secures exclusive Southeast Asian rights to a growing cell therapy logistics market.
- The ATCLS technology preserves cells at ambient temperature, reactivating them at point of use via GEDM platform for real-time control.
- This partnership could make life-saving cell and gene therapies more accessible and affordable, reducing reliance on fragile cold chains.
- Ambient temperature logistics could slash costs and expand reach for cell therapies, with the global market projected to hit $16.95B by 2035.
Impact - Why it Matters
This strategic partnership positions AcroMeta at the forefront of a transformative shift in cell and gene therapy logistics. By investing in ATCLS, which enables ambient-temperature transport of living cells, the company stands to disrupt a market currently reliant on expensive and fragile cold chains. This move could significantly lower costs and expand access to life-saving therapies across Southeast Asia, potentially accelerating the adoption of advanced treatments like CAR-T and regenerative medicine. For shareholders, it offers a diversification into a high-growth sector, while for the healthcare industry, it heralds a new era of efficient and scalable distribution of biological materials.
Summary
Singapore-listed AcroMeta Group Limited has announced a strategic move into the cell and gene therapy logistics sector by signing a non-binding term sheet with Macro HRD SG Pte. Ltd. to acquire a stake in Macro-ATCLS Pte. Ltd., the commercial arm for the innovative Ambient Temperature Cellular Logistics (ATCLS) technology. This technology promises to transform the transport of living cells and temperature-sensitive biological materials by eliminating the need for traditional cold chains, using proprietary preservation and reactivation methods coupled with a Gradient Equilibrium Decision Modeling (GEDM) platform for real-time oversight. AcroMeta also holds an option for an exclusive license to deploy this platform across Southeast Asia, with rights to appoint sub-licensees and a first right to acquire additional territories.
The partnership targets high-growth markets including stem cells, CAR-T therapy, and organ transplantation, with the global cell-and-gene-therapy 3PL market projected to surge from US$1.81 billion in 2025 to US$16.95 billion by 2035. Macro estimates a Serviceable Addressable Market (SAM) of approximately US$14.5 billion by 2032 for defined segments. AcroMeta's Executive Director, Mr. Lawrence Toh, expressed excitement about the potential to build a presence in this rapidly expanding industry as part of the group's long-term growth strategy, which continues to evaluate strategic opportunities for shareholder value creation.
Macro HRD, established in 2024, is a Singapore-based biotech firm integrating advanced biology and AI/ML to develop therapeutics for infectious diseases, but its ATCLS technology is positioned as a category-creating solution to reduce costs and geographical limitations of cold-chain logistics. The proposed partnership aligns with AcroMeta's goal to diversify beyond its core facility management services, and this news was distributed via NEWMEDIAWIRE. For more details, see the original release on www.newmediawire.com.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, AcroMeta Partners to Revolutionize Cell Logistics with ATCLS Technology
